Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Jan 2017

Fidler Meredith C, Beusmans Jack, Panorchan Paul, Van Goor Fredrick

Abstract excerpt

Ivacaftor, a CFTR potentiator that enhances chloride transport by acting directly on CFTR to increase its channel gating activity, has been evaluated in patients with different CFTR mutations. Several previous analyses have reported no statistical correlation between change from baseline in ppFEV1 and reduction in sweat chloride levels for individuals treated with ivacaftor. The objective of the post hoc analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Chloride Channel Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chlorides

Share to Clinical Trials as Topic

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Forced Expiratory Volume

Share to Quinolones

Source

Identifiers

PMID: 27773592
DOI: 10.1016/j.jcf.2016.10.002

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor.PMID 27773592Read ↗

Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.Semantic proximity Read ↗

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.Semantic proximity Read ↗

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read ↗

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Semantic proximity Read ↗

Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.Semantic proximity Read ↗

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.Semantic proximity Read ↗

Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study.Semantic proximity Read ↗

Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis.Semantic proximity Read ↗

CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.Semantic proximity Read ↗

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.Semantic proximity Read ↗

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.Semantic proximity Read ↗

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.